BRAF and neoplasm: On the other hand, we observed marked differences for the anti‐PD‐1 therapy, with median PFS being more than twice longer than reported for nivolumab in melanoma patients with either non‐mutated tumours (5.1 months) in the Checkmate 066 trial27 or irrespectively of BRAF tumour status (5.6 months for BRAF mutated and 6.9 months in unselected patients) in the Checkmate 067 trial.5